Professional profile
About Shan
Regional Partner | Chinese mainland capital markets; private equity & investment funds; litigation & arbitration
Shan Peng is a regional partner in Zhong Lun Law Firm's Wuhan office whose principal practices are Chinese mainland capital markets, private equity and investment funds, and litigation and arbitration. Her official profile describes significant experience in domestic IPOs, transfers of listing, refinancing of listed companies, major asset restructurings, NEEQ and Beijing Stock Exchange transactions, private placements, investment and M&A.
Read full profile
Peng's profile is particularly differentiated by her work on the pathway from the Beijing Stock Exchange to ChiNext. Zhong Lun states that she managed the listing of Taixiang on the Beijing Stock Exchange and the subsequent transfer of its listing to ChiNext, described by the firm as the first transaction of its kind. This experience makes her highly relevant to growth companies in central China considering whether their current market venue continues to fit their capital and strategic needs.
Her capital-markets work is not limited to public offerings. The profile also describes participation in private equity fund formation, M&A funds, investment due diligence, post-investment management and private placements. This provides a useful bridge between private financing and public markets. A company preparing for an IPO or listing transfer often carries investor rights, equity incentives, historic financing terms and governance arrangements that need to be cleaned up before filing.
Peng has also advised listed companies on internal-control standardization, information disclosure compliance and corporate governance optimization. That post-listing experience matters because the legal work is not finished when the shares begin trading. Listed companies must maintain disclosure systems, related-party transaction controls, board procedures and equity-incentive compliance.
Her representative matters include life-sciences and technology companies, which aligns well with Wuhan's Optics Valley and biotechnology ecosystem. Growth-stage science and technology companies often use several funding channels over time: government-guided funds, venture capital, strategic investors, NEEQ or BSE listing and, in suitable circumstances, a transfer to another exchange board. Each step can change governance and disclosure expectations.
For a company considering a listing transfer, the central issue is not simply eligibility. Management needs to assess whether historic related-party transactions, customer concentration, equity incentives, accounting policies, internal controls and investor rights are ready for the stricter disclosure and market environment. The company may need twelve to twenty-four months of remediation before filing.
Peng's private-fund practice is also relevant because state-owned and government-guided funds are important investors in Wuhan's technology economy. These investors may have special internal approval, valuation and exit requirements. The company needs to understand how investor rights will interact with a future public listing or transfer.
The litigation and arbitration element of her practice adds another perspective. Capital-market preparation can be disrupted by shareholder disputes, repurchase claims or disagreements over investment agreements. A pending dispute can affect disclosure, control and listing timetable. Transaction counsel who understands dispute risk can design cleaner exit or termination arrangements for investor rights.
Capability
